Docon Technologies Sells 9.9% Stake in Thyrocare for Rs 986 Crore
Docon Technologies divests 9.9% of Thyrocare, lowering its stake to 51.02%. The sale attracted major institutional investors.
Docon Technologies, a prominent promoter of Thyrocare Technologies Ltd, has divested a 9.9% stake in the company, translating to Rs 986 crore. The sale, executed through a series of bulk and block deals, occurred across both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) on Thursday.
Details of the Transaction
The transaction involved the sale of 1,57,69,696 equity shares. Of these, more than 1.31 crore shares were offloaded through block deals, while 10 lakh shares were sold in bulk on the NSE. Additionally, 16.01 lakh shares were transacted in a bulk deal on the BSE. The shares were priced between Rs 624 and Rs 631.71 each, culminating in a total transaction value of Rs 985.86 crore.
Impact on Shareholding and Market Response
Following this transaction, Docon's holding in Thyrocare reduced from 60.92% to 51.02%. The stake sale witnessed participation from several institutional investors, including HSBC Mutual Fund, DSP Mutual Fund, ICICI Prudential Mutual Fund, and Aditya Birla Sun Life Mutual Fund. Other notable buyers included WhiteOak Capital Mutual Fund, ITI Mutual Fund, Kotak Mahindra Life Insurance Company, Tata AIA Life Insurance, Morgan Stanley, Citigroup Global Markets, HBM Healthcare Investments (Cayman), and the Kuwait Investment Authority.
The market reacted positively to the transaction, with Thyrocare Technologies' shares rising nearly 3% to Rs 621.95 on the NSE and over 2% to Rs 622 on the BSE on Friday.
Historical Context and Future Implications
This sale follows Docon's previous divestment of a 10% stake in Thyrocare for Rs 667 crore in October of the previous year. The continued reduction in Docon's stake suggests a strategic shift, possibly aimed at diversifying its investment portfolio or refocusing its business strategy.
The entry of substantial institutional investors is likely to influence Thyrocare's governance and strategic direction, potentially impacting its operational and financial performance in the future. The influx of capital and the involvement of global investors could also enhance Thyrocare's growth prospects and market competitiveness.